Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Compounds in development (PDF 0.1 MB) section of the 2025 Annual Report  

Show Filters
Phase 1X
Clear All
Showing 22 results
  • AAA603
    177Lu-NeoB
    Breast cancer
    Oncology: Solid Tumors Phase 1 Radioligand therapy target GRPR
  • AMO959
    AMO959
    Prostate cancer
    Oncology: Solid Tumors Phase 1 DNA repair
    Lead Indication
  • CYX082
    farabursen
    Autosomal dominant polycystic kidney disease
    Cardiovascular, Renal and Metabolic Phase 1 MIR17 inhibitor
    Lead Indication
  • DFT383
    DFT383
    Cystinosis
    Neuroscience Phase 1 CTNS gene delivery
    Lead Indication
  • DZR123
    tulmimetostat
    Prostate cancer
    Oncology: Solid Tumors Phase 1 EZH1, EZH2 inhibitor
  • ECI830
    ECI830
    Breast cancer
    Oncology: Solid Tumors Phase 1 CDK2 inhibitor
    Lead Indication
  • EDK060
    EDK060
    Charcot-Marie-Tooth disease
    Neuroscience Phase 1
    Lead Indication
  • ESP359
    ESP359
    Solid tumors
    Oncology: Solid Tumors Phase 1 Radioligand therapy target DLL3
    Lead Indication
  • FXX489
    177Lu-NNS309
    Solid tumors
    Oncology: Solid Tumors Phase 1 Radioligand therapy target FAP
    Lead Indication
  • GCJ904
    GCJ904
    Solid tumors
    Oncology: Solid Tumors Phase 1
    Lead Indication
  • IPX643
    IPX643
    Inflammation-driven diseases
    Immunology Phase 1
    Lead Indication
  • ITU512
    ITU512
    Sickle cell disease
    In-market Brands and Global Health Phase 1 HbF inducing agent
    Lead Indication
  • NIO752
    NIO752
    Progressive supranuclear palsy
    Neuroscience Phase 1 Tau antisense oligonucleotide
    Lead Indication
  • NIO752
    NIO752
    Alzheimer’s disease
    Neuroscience Phase 1 Tau antisense oligonucleotide
  • OJR520
    OJR520
    CKD
    Cardiovascular, Renal and Metabolic Phase 1
    Lead Indication
  • PIT565
    PIT565
    Systemic lupus erythematosus
    Immunology Phase 1 Anti-CD19, Anti-CD2, Anti-CD3
  • PIT565
    PIT565
    Rheumatoid arthritis
    Immunology Phase 1 Anti-CD19, Anti-CD2, Anti-CD3
  • YMI024
    YMI024
    CVRR
    Cardiovascular, Renal and Metabolic Phase 1
    Lead Indication
  • YTB323
    rapcabtagene autoleucel
    Rheumatoid arthritis and severe, refractory Sjögren’s disease
    Immunology Phase 1 CD19 CAR-T
  • YTB323
    rapcabtagene autoleucel
    Relapsing multiple sclerosis
    Neuroscience Phase 1 CD19 CAR-T
Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.